Sartorius collaborates with Sanofi to commercialize end-to-end platform for
downstream process intensification

EQS-News: SARTORIUS AG / Key word(s): Alliance
Sartorius collaborates with Sanofi to commercialize end-to-end platform for
downstream process intensification (news with additional features)

13.05.2024 / 15:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Göttingen, Germany | May 13, 2024
Sartorius collaborates with Sanofi to commercialize end-to-end platform for
downstream process intensification

  * Sartorius selected as preferred partner for development and
    commercialization of integrated and continuous biomanufacturing (ICB)
    platform

* Modular platform will combine highest flexibility with standardization

  * ICB supports lower resource consumption and higher productivity,
    enabling more affordable patient care and sustainable bioprocessing

  * Collaboration demonstrates Sartorius' leading position in the field of
    process intensification

The life science group Sartorius is collaborating with biopharmaceutical
company Sanofi to develop an end-to-end platform for integrated and
continuous downstream bioprocessing. Selected as a preferred supplier,
Sartorius will contribute its engineering and manufacturing expertise to
commercialize ICB platforms based on prototypes developed by Sanofi. In
return, Sanofi will grant Sartorius exclusive access to its know-how and
patents related to the ICB platform.

Sartorius is committing to the rapid development of hardware, consumables
and process automation for diverse applications and volumes from development
to commercial scale. As part of the collaboration and license agreement,
Sartorius will exclusively commercialize the ICB platform offering to
customers worldwide.

'Technological innovation is crucial for biopharmaceutical companies to
significantly reduce the cost of drug manufacturing - while improving the
environmental footprint of their operations - and ultimately getting
life-saving drugs to patients faster. As the biologics landscape becomes
more diverse, teaming up with Sanofi is an excellent basis for developing a
unique modular platform that combines flexibility with the advantages of
intensified bioprocessing. This collaboration will help Sartorius to further
expand its position as a leading company in the field of integrated and
continuous bioprocessing,' said Jan Schäfer, Head of Separation Systems at
Sartorius.

Integrated continuous biomanufacturing is an advanced approach to the
production of biopharmaceuticals. The concept aims to maximize efficiency by
enabling uninterrupted and steady materials flow, as opposed to traditional
batch methods, and by integrating multiple unit operations into a lean
process setup. ICB reduces the overall process footprint, leading to lower
raw material and energy consumption, higher productivity, and less waste.

Sartorius offers a wide array of applications for process intensification in
both upstream and downstream, ranging from high-throughput tools for process
development to scalable, flexible manufacturing solutions.


A profile of Sartorius
Sartorius is a leading international partner of life sciences research and
the biopharmaceutical industry. With innovative laboratory instruments and
consumables, the Group's Lab Products & Services division focuses on
laboratories performing research and quality control at pharmaceutical and
biopharmaceutical companies as well as academic research institutes. The
Bioprocess Solutions division, with its broad product portfolio focusing on
single-use solutions, helps customers manufacture biotech medications,
vaccines, and cell and gene therapies safely, rapidly, and economically. The
company, based in Göttingen, Germany, has a strong global reach with around
60 production and sales sites worldwide. Sartorius regularly expands its
portfolio through the acquisition of complementary technologies. In 2023,
the company generated sales revenue of around 3.4 billion euros. Currently,
around 14,600 employees are working for customers around the globe.

Visit our newsroom and follow Sartorius on LinkedIn.


Contact
Leona Malorny
Head of External Communications
+49 (0)551.308.4067
Leona.malorny@sartorius.com


---------------------------------------------------------------------------

Additional features:

File: https://eqs-cockpit.com/c/fncls.ssp?u=3fd21bcbf3fae9c3debd05b5e2ff3eda
File description: 20240513_SAG_Media Release_Sartorius collaborates with
Sanofi

---------------------------------------------------------------------------

13.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        SARTORIUS AG
                   Otto-Brenner-Straße 20
                   37079 Göttingen
                   Germany
   Phone:          +49.(0)551-308.0
   Fax:            +49.(0)551-308.3289
   E-mail:         info@sartorius.com
   Internet:       www.sartorius.com
   ISIN:           DE0007165607, DE0007165631
   WKN:            716560 , 716563
   Indices:        DAX, TecDAX
   Listed:         Regulated Market in Frankfurt (Prime Standard),
                   Hanover; Regulated Unofficial Market in Berlin,
                   Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate
                   Exchange
   EQS News ID:    1901531

End of News EQS News Service
---------------------------------------------------------------------------

1901531 13.05.2024 CET/CEST